Clinical trials: Bile Duct Neoplasms
Colorectal Cancer, Esophageal Cancer
Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of two different vaccines in treating patients who have cancer of the…
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00012246
- Testing
- carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Pancreatic Cancer, Liver Cancer
Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program
Major surgery is a stressful procedure; good recovery after surgery is important to patients and their doctors. Studies done at the McGill University Health Centre (MUHC) with cancer patients awaiting surgery have shown that…
- Conditions
- Pancreatic Cancer, Liver Cancer, Bile Duct Cancer, Hepatobiliary Cancer
- Trial name
- NCT03475966
- Testing
- Exercise, Nutrition, Relaxation techniques
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Pancreatic Cancer
Radiofrequency Probe for Management of Unresectable Bile Duct and Pancreatic Cancer
The purpose of this study is to determine whether the use of an FDA approved endoscopic bipolar catheter (EndoHPB) will ablate tissue in malignant tumors within the pancreatic ducts.
- Trial name
- EndoHPB (NCT02042859)
- Testing
- Endoscopic Bipolar RadioFrequency Probe used to remove tumors in bile duct to manage Pancreatic Cancer
- Volunteers
- 40 people
- Sponsor
- Ochsner Health System
Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
Phase II trial to study the effectiveness of erlotinib in treating patients who have unresectable liver, bile duct, or gallbladder cancer.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct
- Trial name
- NCT00033462
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Biliary Tract Neoplasms, Pancreatic Neoplasms
The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer
Evaluate the efficacy and safety of Trilaciclib for myeloprotection prior to chemotherapy in advanced cholangiocarcinoma or pancreatic cancer.
- Trial name
- NCT07160283
- Testing
- Bile duct cancer cohort, Pancreatic cancer cohort
- Volunteers
- 96 people
- Sponsor
- The Second Affiliated Hospital of Shandong First Medical University
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Bile Duct Neoplasms
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
Doctors at Memorial Sloan Kettering Cancer Center and at other institutions study normal and cancer cells. To study these cells we need to have human tissue, body fluids, and blood.
- Conditions
- Esophageal Cancer, Bile Duct Neoplasms, Gastric Cancer, Liver Cancer
- Trial name
- NCT00582647
- Where
- United States
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gallstone, Cholangitis
Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images
The Institute of Imaged-Guided Surgery (IHU Strasbourg) has two clinical Magnetic Resonance Imaging (MRI) scanners, one with a 3T (3 Teslas) magnetic field used for diagnosis, the other with a magnetic field of 1,5T (1,5 Teslas)…
- Conditions
- Gallstone, Cholangitis, Cholangiocarcinoma, Pancreatitis
- Trial name
- BiliFast (NCT03852836)
- Testing
- ultra-rapid acquisition of bile ducts images
- Where
- France
- Volunteers
- 53 people
- Sponsor
- IHU Strasbourg
Obstructive Jaundice, Bilio-pancreatic Tumor
Endoscopic Ultrasound Evaluation of the Common Bile Duct in Patients With Obstructive Jaundice Due to Bilio-pancreatic Malignancies (ECCO Trial)
To assess the size of the common bile duct in a large cohort of patients with jaundice following a malignant tumor of the head of the pancreas or the distal bile duct receiving a diagnostic EA for biopsy and / or for evaluation…
- Trial name
- ECCO (NCT05155475)
- Testing
- Ultrasound endoscopy
- Where
- France
- Volunteers
- 20 people
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Primary Sclerosing Cholangitis, PSC
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.
- Conditions
- Primary Sclerosing Cholangitis, PSC, Cholangiocarcinoma
- Trial name
- NCT04753996
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Cholestatic Liver Disease, Intrahepatic Cholestasis
Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis
Genotype-phenotype relationship between adult cryptogenic cholestasis and mutations in genes responsible for progressive familial intrahepatic cholestasis
- Conditions
- Cholestatic Liver Disease, Intrahepatic Cholestasis, Progressive Familial Intrahepatic Cholestasis, Hepatobiliary Cancer
- Trial name
- NCT06781242
- Where
- 2 sites in Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
RATIONALE: Drugs used in chemotherapy, such as capecitabine and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00789958
- Testing
- capecitabine, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy
- Where
- 251 sites in United States
- Volunteers
- 105 people
- Sponsor
- SWOG Cancer Research Network
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Gallbladder Carcinoma, Metastatic Cholangiocarcinoma
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
This randomized phase II trial studies how well atezolizumab with or without cobimetinib works in treating patients with bile duct cancer that has spread to other places in the body (metastatic) and cannot be removed by surgery…
- Conditions
- Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT03201458
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 41 sites in United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Hepatopancreaticobiliary (HPB) Malignancy, Gall Bladder Cancer
Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy
1. In biliary tract malignancies, achieving a microscopically clear resection margin (R0) is considered the only treatment for a cure. 2.
- Conditions
- Hepatopancreaticobiliary (HPB) Malignancy, Gall Bladder Cancer, Bile Duct Cancer, Pancreatoduodenectomy
- Trial name
- HPD_single (NCT06631352)
- Testing
- Hepatopancreatoduodenectomy
- Volunteers
- 50 people
- Sponsor
- Seoul National University Hospital
Pancreatic Cancer, Sepsis
Colonization of Bile Ducts and Postoperative Infectious Complications of Pancreaticoduodenectomies
The aim of the present prospective study was, first, to verify the correlation between biliary colonization and postoperative infectious complications, and secondarily to asses morbidity and mortality for patients who underwent…
- Conditions
- Pancreatic Cancer, Sepsis, Bile Duct Cancer, Duodenal Cancer
- Trial name
- NCT03525067
- Testing
- Bile sampling for bacterial examination
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Central Hospital, Nancy, France
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Neoplasms, Non-Neoplastic
AI Guidance for Biopsy in Suspected Cholangiocarcinoma
Digital single-operator cholangioscopy (DSOC) has emerged as a medical advance with an important role in the evaluation of indeterminate biliary lesions.
- Conditions
- Neoplasms, Non-Neoplastic, Bile Duct Neoplasms, Bile Duct Lesions
- Trial name
- NCT05374122
- Testing
- DSOC with AI biopsy guidance, DSOC biopsy without AI guidance
- Where
- Ecuador
- Volunteers
- 48 people
- Sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
Liver Transplantation, Hepatitis
Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
The purpose of the study is to test the safety and effectiveness of IDN-6556 in preventing liver damage that normally occurs when livers are transported before being transplanted and in the immediate post-transplant period.
- Conditions
- Liver Transplantation, Hepatitis, Cholestasis, Carcinoma, Hepatocellular
- Trial name
- NCT00080236
- Testing
- IDN-6556
- Where
- 13 sites in United States, Germany
- Volunteers
- 99 people
- Sponsor
- Conatus Pharmaceuticals Inc.